Syndax's Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks according to Wall Street analysts.
Syndax Pharmaceuticals Inc (SNDX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Kynam Capital Derrick Tang | 8,520,000 | $104,668,200 | 8.79% | |
| 2. | Eversept Partners Kamran Moghtaderi | 4,212,270 | $51,747,737 | +1127% | 5.26% |
| 3. | Point72 Asset Management Steve Cohen | 4,008,700 | $49,246,881 | +110% | 0.11% |
| 4. | Citadel Investment Group Ken Griffin | 2,914,882 | $35,809,326 | +168% | 0.01% |
| 5. | Kingdon Capital Mark Kingdon | 2,000,000 | $24,570,000 | 2.6% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 3,000 | $0.00 | 93,746 | 2025-05-19 | Filing | |
| $9.00 | 11,765 | $105,826.18 | 35,165 | 2025-05-16 | Filing | |
| $8.99 | 5,000 | $44,950.00 | 79,000 | 2025-05-19 | Filing | |
| $9.11 | 10,000 | $91,120.00 | 100,000 | 2025-05-19 | Filing | |
| $20.03 | 1,250 | $25,037.25 | 52,623 | 2024-06-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.05 | 7,814 | $117,563.97 | 300,121 | 2025-03-04 | Filing | |
| $15.50 | 3,777 | $58,558.61 | 90,746 | 2025-02-10 | Filing | |
| $15.50 | 13,288 | $206,017.15 | 300,121 | 2025-02-10 | Filing | |
| $15.50 | 4,618 | $71,597.47 | 85,095 | 2025-02-10 | Filing | |
| $18.27 | 52,855 | $965,401.86 | 17,836 | 2023-08-09 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,039,987 | $19,104,478 | 0.03% | |
| 2. | 822 | $7,698 | 0% | |
| 3. | 96 | $899 | 0% | |
| 4. | 71 | $665 | 0% | |
| 5. | 23 | $215 | 0% |
News See All
16 Most Promising Stocks According to Wall Street Analysts
On July 3, Scott Wren, Wells Fargo senior global market strategist, and Adam Crisafulli, Vital Knowledge founder, joined 'Closing Bell Overtime' on CNBC to talk about the current market conditions.
Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best biotech stocks to invest in now.
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Syndax First Quarter 2025 Earnings Conference Call. Today's call is being recorded.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2024 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Syndax Fourth Quarter and Full Year 2024 Earnings Conference Call. Today's call is being recorded.
10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
The biotechnology sector is expanding quickly due to rising demand for novel therapies, technological advances, and government assistance.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2024 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All participants have been placed in a listen-only mode.
10 Best Small-Cap Healthcare Stocks To Buy Now
In difficult economic times, healthcare equities are sometimes regarded as a defensive investment.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q2 2024 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Syndax Second Quarter 2024 Earnings Conference Call. Today's call is being recorded.
Billionaire Hedge Funds
